Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05723055 · ClinicalTrials.gov registry record · Phase 2
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
A Phase 2 study of Hodgkin Lymphoma, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT05723055: Recruiting Phase 2 study of Hodgkin Lymphoma, sponsored by University of Utah.
NCT05723055 is a Phase 2 study of Hodgkin Lymphoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 9 participants, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05723055, a Phase 2 study of Hodgkin Lymphoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This study will mainly look at if the combination works as expected.
Primary Outcome
evaluate the efficacy of combination of Axatilimab (SNDX-6352) and Nivolumab in the study population
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Axatilimab
Study Locations (2)
Michigan
- Karmanos Cancer Institute - Detroit
Utah
- Huntsman Cancer Institute at the University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
What NCT05723055 shows while recruiting
NCT05723055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05723055 reports a single indexed study location in Michigan, Utah.
Frequently Asked Questions
What is clinical trial NCT05723055 about?
NCT05723055 is a clinical study titled "Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma". The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This study will mainly look at if the combination works as expected.
What is the current status of trial NCT05723055?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2023-05-03. Estimated completion is 2028-04.
What conditions does trial NCT05723055 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT05723055?
The interventions under investigation include: Nivolumab (DRUG), Axatilimab (DRUG).
Who is sponsoring clinical trial NCT05723055?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05723055 being conducted?
This trial has 2 study locations across Michigan, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05723055's enrollment target sits among peer trials
9 69th of 71 higher than 3 of 71 other Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI